NEW YORK, Oct. 16, 2019 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP:
Levi & Korsinsky, LLP announces that investigations have commenced on behalf of shareholders of the following publicly-traded companies.
Ra Pharmaceuticals, Inc. (RARX)
Merger Announcement: October 10, 2019
Transaction Details: Under the terms of the deal Ra Pharma shareholders will receive $48.00 in cash for each Ra Pharma share at closing.
To learn more about the RARX investigation and your rights, go to: https://www.zlk.com/mna/ra-pharmaceuticals-inc
Dova Pharmaceuticals, Inc. (DOVA)
Merger Announcement: September 30, 2019
Transaction Details: Under the terms of the deal, an indirect subsidiary of Sobi will commence a tender offer for all outstanding shares of Dova, whereby Dova stockholders will be offered an upfront payment for $27.50 in cash, along with one non-tradeable CVR of $1.50 per share.
To learn more about the DOVA investigation and your rights, go to: https://www.zlk.com/mna/dova-pharmaceuticals-inc
Roan Resources, Inc. (ROAN)
Merger Announcement: October 1, 2019
Transaction Details: Under the terms of the deal, Roan stockholders will receive $1.52 in cash for each share of Roan common stock they own.
To learn more about the ROAN investigation and your rights, go to: https://www.zlk.com/mna/roan-resources-inc
Levi & Korsinsky is a national firm with offices in New York, Connecticut, California, and Washington D.C. The firm's attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities lawsuits and have recovered hundreds of millions of dollars for aggrieved shareholders. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.